233 related articles for article (PubMed ID: 16699638)
1. [Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate].
Rodrigues AM; Hueb M; Santos TA; Fontes CJ
Rev Soc Bras Med Trop; 2006; 39(2):139-45. PubMed ID: 16699638
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
3. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
4. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
Vargas-Gonzalez A; Canto-Lara SB; Damian-Centeno AG; Andrade-Narvaez FJ
Am J Trop Med Hyg; 1999 Dec; 61(6):960-3. PubMed ID: 10674678
[TBL] [Abstract][Full Text] [Related]
5. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
6. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil.
Teixeira AC; Paes MG; Guerra Jde O; Prata A; Silva-Vergara ML
Rev Inst Med Trop Sao Paulo; 2008; 50(3):157-60. PubMed ID: 18604416
[TBL] [Abstract][Full Text] [Related]
7. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
[TBL] [Abstract][Full Text] [Related]
8. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Romero GA; Guerra MV; Paes MG; Macêdo VO
Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
Momeni AZ; Reiszadae MR; Aminjavaheri M
Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
Bogenrieder T; Lehn N; Landthaler M; Stolz W
Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent cutaneous Leishmaniasis.
Momeni AZ; Aminjavaheri M
Int J Dermatol; 1995 Feb; 34(2):129-33. PubMed ID: 7737774
[TBL] [Abstract][Full Text] [Related]
16. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
17. Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis.
Antonio Lde F; Fagundes A; Oliveira RV; Pinto PG; Bedoya-Pacheco SJ; Vasconcellos Ede C; Valete-Rosalino MC; Lyra MR; Passos SR; Pimentel MI; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(5):375-80. PubMed ID: 25229216
[TBL] [Abstract][Full Text] [Related]
18. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
Oliveira-Neto MP; Schubach A; Mattos M; Goncalves-Costa SC; Pirmez C
Am J Trop Med Hyg; 1997 Dec; 57(6):651-5. PubMed ID: 9430521
[TBL] [Abstract][Full Text] [Related]
19. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
20. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]